PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

THE LEVEL OF PSA AND FIBRINOLYTIC ACTIVITY IN THE PATIENTS WITH PROSTATIC CARCINOMA
Article published in Urologia Polska 1996/49/4.

authors

Zbigniew Ziętek 1, Iza Iwan-Ziętek 1, Maria Kotschy 2, Zbigniew Wolski 1
1 Z Katedry i Kliniki Urologii Akademii Medycznej w Bydgoszczy
Kierownik: doc. dr hab. med. Z Wolski
2 Z Katedry i Zakładu Patofizjologii Akademii Medycznej w Bydgoszczy
Kierownik: prof. dr hab. med. M. Kotschy

keywords

prostate prostatic carcinoma PSA fibrinolytic activity

summary

In the 20 patients with prostatic carcinoma (PC) and 18 patients with benign prostatic
hyperplasia (BPH) as a control group the level of PSA in Comparison with fibrinolytic
activity was examined. Based on a shorter ELT and a decreased of a2-AP activity a
stronger activation of fibrinolysis in the patients with PC was shown. The level of t-
PA:Ag was similar in both groups but the level of PSA was higher in the patients with
PC. Approximately 20% patients with PC had a normal level of PSA but values of t-
PA: Ag were an increased in those patients. However, there was no correlation between
values of t-PA:Ag and PSA in the patients with PC and BPH.

references

  1. [1] Christensson, A., i wsp:. Serum prostate specific antigen complexed to a,-anti-
  2. chymotripsin as an indicator of prostate cancer. J. Urol. (1993), 150,100.
  3. [2] Christensson, A, i wsp.: Enzymatic activity of prostate specific antigen and its reactions
  4. with extracellular serine proteinase inhibitors. Eur. J. Biochem. (1990), 194,755.
  5. [3] Dano, K, i wsp.: The urokinase receptor. Protein structure and role in plasmino-
  6. gen activation and cancer invasion. Fibrinolysis (1994), 8, Suppl. 1,189.
  7. [4] Debruyne, F. M. J., Schalken, J.A.: The contribution of molecular and cellular bio-
  8. logy in the understanding of genitourinary tumors. Urol. Pol. Supl. (1994), 3A, 2.
  9. [5] Espana, E, i wsp.: Functionally active protein C inhibitor/plasminogen activator
  10. inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentra-
  11. tions in human seminal plasma and complexes with prostate specific antigen. Th-
  12. romb. Res. (1991), 64, 309.
  13. [6] Iwan-Ziętek, I., i wsp.: Tkankowy aktywator plazminogenu i jego inhibitor oraz
  14. inne parametry układu fibrynolizy we krwi chorych operowanych z powodu łagod-
  15. nego rozrostu gruczołu krokowego. Pol. Tyg. Lek. (1992), 49-50,1096.
  16. [7] Kestei; R. C.: Plasminogen activator in the human prostate. J. Clin. Path. (1969), 22,442.
  17. [8] Kirchheimer, 1, Binder, B. R.: Localization and immunological characterization of
  18. plasminogen activators in human prostate tissue. Haemostas. (1983), 13,358.
  19. [9] Kuzaka, B., Cieślak, A.: Skaza krwotoczna w przebiegu raka gruczołu krokowego z
  20. przerzutami. Urol. Pol. (1981), 34,3.
  21. [10] Lilja, H., i wsp.: Prostate specific antigen in serum occurs predominantly in com-
  22. plex with alpha 1-antichymotripsin. Clin. Chem. (1991), 37,1618.
  23. [11] Marczyńska, A., Kulpa, J:. Swoisty antygen sterczowy (PSA): ocena użyteczności w
  24. klinice raka stercza.
  25. [12] Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful
  26. tumor marker for adenocarcinoma of the prostate.
  27. [13] Okajiama, K, i wsp:. Direct evidence for systemic fibrinogenolysis in a patient with
  28. metastatic prostatic cancer. Thromb. Res. (1992), 66,717.
  29. [14] Rapaport, S. J., Chapman, C. G., Aures, S. B.: Coexistent hypercoagulability and
  30. acute hypofibrinogenemia in patient with prostatic carcinoma. Am. J. Med. (1959),
  31. 7,144.
  32. [15] Sumyioshi, K, i wsp.: Plasminogen activator in human breast cancer. Int. J. Cancer
  33. (1992), 50 (3), 345.
  34. [16] Tagnon, H. J., Whitmore, W F.Jr., Schulman, M. R.: Fibrinolysis in metastatic cancer
  35. of prostate. Cancer (1952), 5,93.
  36. [17] Wang,M. C, iwsp.: Purification of human prostate specific antigen. Invest. Urol.
  37. (1979), 17, 159.
  38. [18] Watt, K. W.K., i wsp.: Human prostate specific antigen: structural and functional
  39. sililarity with serine proteases. Proc. Nati. Acad. Sci. U.S.A. (1986), 83,3166.
  40. [19] Wolff, J. M., i wsp.: Differentiationa of bening prostatic hyperplasia and prostate
  41. cancer employing prostatic - specific antigen density. Eur. Urol. (1994), 4,295.
  42. [20] Zacharsky, L. R., i wsp.: Pathways of coagulation/fibrinolysis activation in malig-
  43. nancy. Semin. Thromb. Haemost. (1992), 18,104.